Contact Uscontact

Parc Euromédecine, Cap Gamma
1682 Rue de la Valsière - CS17383
34189 Montpellier cedex 4 - FRANCE

Office +33 (0)4 67 727 670
FAX : +33 (0)4 67 727 679

Out-LicensingOut-Licensing 

3 oncology-focused projects, including novel targeted therapies (molecules and antibodies), under development and potentially available for licensing or collaboration.
» Read more ...

Newsrss

04/25/13 : OriBase Pharma is entitled to taxes return for investment

Thanks to a first round of fund raising realized successfully ( 1 500 000€), involving 52 investors, we were able...
» Read more ...

OriBase Pharma Scientific Approach

OriBase Pharma scientific approach is based on the development of new and targeted therapies, which has demonstrated over last years to be the most relevant approach (in terms of efficacy and safety) in oncology new drug development over the lattest years.

OriBase Pharma team has developed across the years a sound knowledge in cancer biology with pronounced interest and expertise in the field of kinase inhibitors. The current popularity of kinases as drug targets (at least 15 kinase inhibitors are marketed) is driven by the convergence of several factors:

In contrast to conventional cytotoxic chemotherapy & radiation therapy, OriBase Pharma next generation kinase therapeutics target specific tumor cells. New therapies developed by OriBase Pharma fight cancer with multi-site mechanism of action and reduce mechanisms leading to drug-resistance.